THC, CBD, Delta-8 and K2: Key Differences and Risks in GA

THC, CBD, delta-8 and K2 are not interchangeable names. THC and delta-8 can cause intoxication; CBD is nonintoxicating but can cause adverse effects. K2 and Spice are lab-made synthetic cannabinoids associated with severe harm. A product’s origin, marketing, or label does not establish its safety or FDA approval.

If you are trying to understand something you or a loved one used, similar names can make the picture confusing. A cannabis product, a CBD oil, a delta-8 gummy, and something sold as Spice do not necessarily contain the same compounds or carry the same concerns. This guide for adults in GA separates those categories using NIDA’s cannabis information. It also explains what product descriptions cannot tell you. The goal is not to help you shop or choose a substance, but to make the differences clearer without assuming that a familiar package means a familiar risk.

How do THC and CBD differ?

THC has intoxicating effects, while CBD does not produce intoxication in the same way. That basic distinction belongs in both substance-use education and individualized treatment planning. According to NIDA, delta-9 THC can temporarily change mood, thoughts, and perceptions. CBD is a different cannabinoid found in the cannabis plant, not simply a milder name for THC.

Cannabis is the plant-related category, and cannabinoids are compounds associated with it. Saying that something contains cannabis does not identify every compound in the product. Likewise, saying that two substances come from the same plant does not mean they have identical effects. The distinction between THC and CBD helps explain why plant origin alone cannot answer whether a product causes intoxication.

THC-containing cannabis can impair thinking, memory, and body movement. It can also cause anxiety, panic, or changes in perceptions, particularly under circumstances described by NIDA’s review of cannabis effects. CBD has its own adverse-effect concerns. These are different descriptions, not a simple division between a harmful compound and a harmless one.

These categories describe meaningful differences, but they do not predict exactly how an individual will feel. NIDA identifies ingredients, other drugs taken, underlying medical conditions, and a person’s experience with cannabis among the factors that can affect the response.

What does NIDA say about delta-8 THC?

Delta-8 THC is an intoxicating cannabinoid, not another term for CBD. That matters when describing a concern in outpatient drug treatment or developing an individualized care plan. NIDA states that delta-8 THC products have not been FDA-approved for safe use. Commercial availability should not be mistaken for that approval.

NIDA also reports medical emergencies, including breathing problems, after people consumed large amounts of delta-8-containing products. This is a specific safety concern, not evidence that every exposure produces the same result. If someone has trouble breathing, cannot be awakened, or appears to be in immediate danger, call 911 rather than waiting for a routine treatment conversation.

Research on delta-8 and several other intoxicating cannabinoid compounds remains limited. Limited research means there are unresolved questions about health effects. It does not mean that the substance has been shown to be harmless. The most useful distinctions are straightforward:

• Delta-8 THC can cause intoxication, so describing it as nonintoxicating CBD is inaccurate.
• A product being sold does not establish FDA approval for safe use.
• A familiar product format does not establish familiar ingredients or effects.
• Gaps in research are reasons to acknowledge uncertainty, not to promise safety.

This article does not make claims about whether a particular delta-8 product is legal in GA. Legal status, FDA approval, and health effects are separate issues. None should be used as a shortcut for answering the others.

Why are K2 and Spice not interchangeable with plant cannabis?

K2 and Spice are names used for lab-made synthetic cannabinoids, which are chemically similar to compounds found in cannabis but can produce serious, potentially life-threatening effects. That distinction matters in treatment education and assessment-guided outpatient planning. NIDA describes synthetic cannabinoids separately from plant cannabis, rather than treating those terms as interchangeable.

Chemical similarity does not establish the same safety profile. If something is described as a cannabinoid, that does not mean its effects can be predicted from a previous experience with cannabis flower or CBD. The shared terminology can obscure an important category difference.

The term synthetic describes how a substance is made. It does not, by itself, establish FDA approval or suitability for medical use. NIDA separately explains that certain specific synthetic THC-based medications have FDA approval for particular medical purposes. Those approvals do not extend to everything described as a synthetic cannabinoid, and they do not establish approval for K2 or Spice.

It is equally important not to collapse every unfamiliar cannabinoid into the K2 category. NIDA discusses delta-8 THC and synthetic cannabinoids in separate explanations. Calling them all the same thing would lose information rather than clarify it. An accurate description preserves the name used for the product while acknowledging when the actual ingredients remain uncertain.

Severe symptoms or immediate danger require emergency care. NIDA’s emergency guidance directs people to call 911 or seek an emergency department. Identifying an exact compound should never become a reason to delay that response.

Why does nonintoxicating not mean free of adverse effects?

Nonintoxicating means CBD does not have THC’s intoxicating effects; it does not mean CBD cannot cause unwanted effects. This distinction is relevant to individualized care planning and medication discussions within River City Recovery’s outpatient programs. NIDA lists drowsiness, decreased appetite, vomiting, and diarrhea among possible CBD adverse effects.

Drowsiness and intoxication are not identical descriptions. A person can experience an unwanted effect without having the kind of high associated with THC. Keeping those concepts separate makes it easier to understand why a product marketed as nonintoxicating still deserves attention when someone feels unwell.

There is also a difference between CBD as a compound and the full contents of a product marketed as CBD. NIDA reports that some products contain amounts of CBD different from those on their labels, and some have been found to contain THC. A label describing one ingredient therefore may not completely describe the exposure.

NIDA notes that the FDA has approved a particular plant-derived CBD-based medication for seizures associated with rare forms of epilepsy. That is not blanket approval of consumer CBD oils, foods, supplements, or lotions. The approved product and its medical purpose are more specific than the broad word CBD.

What can product labels and marketing fail to establish?

Labels and marketing may fail to establish the actual ingredients, accurate amounts, or evidence for a claimed medical use. Understanding evidence-based treatment and substance-use education means separating a description from proof. NIDA documents CBD labeling discrepancies and explains the limits of cannabis-related FDA approvals.

Words such as natural or plant-derived describe something about origin. They do not establish whether a product causes intoxication, whether its label is accurate, or whether it is an approved treatment. Similarly, marketing a product for sleep, anxiety, pain, or another concern does not itself demonstrate that the product is safe and effective for that purpose.

Several separate uncertainties can sit behind one familiar-looking package:

• Ingredient identity: a product marketed as CBD may also contain THC.
• Ingredient amount: the CBD amount may differ from the amount listed.
• Medical claims: a proposed use is not the same as an FDA-approved indication.
• Individual response: ingredients, other substances, and health conditions can affect what happens.

These limits do not prove that every label is inaccurate. They explain why the label alone cannot settle every safety question. A product name can be useful information while still leaving uncertainty about contents. A careful explanation should preserve both facts rather than assuming either complete accuracy or complete deception.

FDA approval is also specific. NIDA explains that the FDA has not approved a product containing whole cannabis plant material for any purpose, while certain cannabinoid-based medicines have specific approvals. Those statements can both be true because they concern different products, not a single approval covering the entire cannabis category.

Why does identifying the product matter in assessment?

Identifying the product helps distinguish what may have been taken from what the packaging seemed to promise. It supports matching drug treatment to the substance involved and assessment within River City Recovery’s outpatient programs. The useful distinction is not whether a name sounds natural or medical, but which substance, effects, and health concerns are actually involved.

An assessment considers more than the category printed on a package. NIDA recommends tailoring treatment to drug-use patterns and related medical, mental health, and social problems. The product involved can help clarify that picture, but a product name alone cannot diagnose a substance use disorder or determine the appropriate level of care.

For example, anxiety can occur with THC-containing cannabis, but anxiety can also be a separate mental health concern. The relationship cannot be established simply by recognizing one symptom. NIDA explains that substance use and other mental disorders can have overlapping symptoms and are generally better addressed together when both are present. Assessment helps avoid treating every symptom as proof of one cause.

Knowing the exact contents is not a requirement for seeking help. Uncertainty is itself part of the information available. You do not need to solve a labeling discrepancy or identify an unknown compound before making contact. A clear distinction between what is known, what was marketed, and what remains uncertain is more accurate than guessing.

River City Recovery provides adult PHP, Intensive Outpatient Program (IOP), Evening IOP, outpatient therapy, assessments, medication management, and coordination or referrals in Columbus, GA. Its outpatient programs are not emergency care or medical detox. You can explore the verified IOP or PHP pages, or contact River City Recovery at 706-617-4970 without choosing a program first.

For immediate danger or severe symptoms, call 911. For emotional distress or a substance-use or mental-health crisis, call or text 988 for crisis support, as outlined in NIDA’s emergency resources.